Clinical Topics
News
BTK inhibitor reduces MS enhancing lesions
However, neither the 75-mg nor 25-mg dosing regimens significantly reduced Expanded Disability Status Scale scores, compared with placebo.
News
FDA approves Mavenclad for treatment of relapsing MS
Cladribine (Mavenclad) is the first short-course oral therapy for adult patients with relapsing/remitting or active secondary progressive MS.
Conference Coverage
Neurologists grappling with patients who embrace ‘stem cell tourism’
DALLAS – The unethical practice of offering unproven cellular preparations to patients is rising in multiple sclerosis.
Video
Don’t forget social determinants of health in minority MS patients
DALLAS – Keep race and ethnicity in mind when caring for patients with multiple sclerosis, says Dr. Lilyana Amezcua.
Conference Coverage
CSF biomarker clusters correlate with MS severity
DALLAS – Proteins related to astrocytes and microglia are elevated in the CSF of patients with multiple sclerosis and correlate with MS disease...
Video
Smartphone-based visual tests for MS patients show promise
DALLAS – Researchers have developed tests to detect visual pathway disturbances, with an eye toward ease of use.
Conference Coverage
Spinal cord atrophy found to be accelerated in subset of RRMS patients
DALLAS – The finding marks the first of its kind.
News
Early intensive treatment of MS may benefit patients
Real-world population-based cohort study finds better outcomes at 5 years with first-line treatment with a high-efficacy therapy.
News
DMTs, stem cell transplants both reduce disease progression in MS
News
Daclizumab beta may be superior to interferon beta on MS disability progression
A post hoc analysis indicates that daclizumab beta has superior efficacy, compared with interferon beta-1a, regardless of patients’ baseline...